Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-03-29
2000-08-01
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 13, 514 14, 514 56, 514 59, A61K 3816, A61K 31715, C12N 912
Patent
active
060967056
ABSTRACT:
The present invention relates to a method of inhibiting desensitization of a cell to the effects of a compound. The method comprises contacting the cell with an agent capable of inhibiting phosphorylation, by a protein kinase, of a receptor for the compound present on the surface of the cell. The present invention also relates to a method of screening a compound for its ability to inhibit desensitization. The method comprises: i) contacting a receptor specific kinase-containing sample with the compound under conditions such that interaction between receptor specific kinase present in the sample and the compound can occur, and
REFERENCES:
The Journal of Biological Chemistry, vol. 262, No. 36, 17251-17253, Dec. 25, 1987.
Bulletin of the European Physiopathology of Respiration, vol. 21(5) G Cross, pp. 355-435.
The Journal of Biological Chemistry, vol. 264, 6707-6710, Apr. 25, 1989.
The Journal of Biological Chemistry, vol. 262, 6468-6471, May 15, 1987.
Proc. Natl. Acad. Sci. USA, vol. 83, 2797-2801, May 1986.
Nambi et al, "Desensitization of the turkey erythrocyte beta-adrenergic receptor n a cell-free system. Evidence that multiple protein kinases can phosphorylate and desensitize the receptor", The Journal of Biological Chemistry, vol. 260, No. 4, Feb. 24th 1985, pp. 2165-2171.
Vegesna et al, "Staurosporine inhibits protein kinase C and prevents phorbol ester-mediated leukotriene D4 receptor desensitization in RBL--1 cells", Molecular Pharmacology, vol. 33, No. 5, May 1988, pp. 537-542.
Hu et al, "Effects of protein kinase inhibitor 1-(5-isoquinolinylsulfonyl)-2-methylpipe razine, on beta-2 adrenergic receptor activation and desensitization in intact human lymphocytes", The Journal of Pharmacology and Experimental Therapeutics, vol. 249, No. 2, May 1989, pp. 492-498.
Lohse et al, "Inhyibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors", Proceedings of the National Academy of Sciences of USA , vol. 86, No. 9, May 1989, pp. 2991-3442.
Hannun et al, Science, 243: 500-507 (1989).
Lefkowitz et al, J. Biol. Chem., 263 (aa):4993-4996 (1998).
Huganin et al, TIPS, 81:472-477 (1987).
Bulletin of the European Physiopathology of Respiration, vol. 21(5) G. Cross, pp. 355-435.
Hannun et al. Science 243: 500-507 (1989).
Lefkowitz et al J. Biol Chem 263(11):4993-4996 (1988).
Huganir et al. TIPS 81:472-477 (1987).
Blackshear et al. FASEB J. 2: 2957-2969 (1988).
Benovic Jeffrey L.
Caron Marc G.
Lefkowitz Robert J.
Lohse Martin J.
Duke University
Fitzgerald David L.
LandOfFree
Inhibition of agonist-specific desensitization of .beta.2 adrene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of agonist-specific desensitization of .beta.2 adrene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of agonist-specific desensitization of .beta.2 adrene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-663877